Law360, New York (June 23, 2006, 12:00 AM ET) -- Generic drug maker Sandoz Inc.’s efforts to prevent Teva Pharmaceuticals from marketing its generic version of cholesterol drug Zocor have been thwarted, after a judge upheld Teva’s right to a 180-day period of marketing exclusivity.
Sandoz, the generics unit of Novartis, filed a suit in the U.S. District Court for the District of Columbia asking the court to prevent Teva from releasing its generic until Sandoz receives U.S. Food and Drug Administration approval for its version.
The complaint, filed against the FDA, challenged the agency’s “decision...
Teva’s Generic Zocor Exclusivity Upheld
To view the full article, take a free trial now.
